🇺🇸 FDA
Patent

US 8008316

Azonafide derived tumor and cancer targeting compounds

granted A61PA61P35/00

Quick answer

US patent 8008316 (Azonafide derived tumor and cancer targeting compounds) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 30 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
39
CPC classes
A61P, A61P35/00